Phase I evaluation of carboplatin by use of a dosing strategy based on a targeted area under the platinum concentration-versus-time curve and individual glomerular filtration rate in cats with tumors

American Journal of Veterinary Research

Volumn 70, Issue 6, 2009, Pages 770-776

  Bailey, Dennis B ^a,c   Rassnick, Kenneth M ^a   Dykes, Nathan L ^a   Pendyala, Lakshmi ^b  

^a Cornell University ^*  (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c Oradell Animal Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PENTETATE TECHNETIUM TC 99M; PLATINUM;

AREA UNDER THE CURVE; ARTICLE; BLOOD CELL COUNT; BODY WEIGHT; BONE MARROW TOXICITY; CAT; CONTROLLED STUDY; DISEASE SEVERITY; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG SCREENING; FEMALE; GLOMERULUS FILTRATION RATE; MALE; NEUTROPENIA; NONHUMAN; OUTCOME ASSESSMENT; PLASMA CLEARANCE; SINGLE DRUG DOSE; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CAT DISEASES; CATS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLOMERULAR FILTRATION RATE; MALE; NEOPLASMS; POLYVINYLS;

ANIMALIA;

EID: 67649506546     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.70.6.770     Document Type: Article

References (31)

1. Theon AP, VanVechten MK, Madewell BR. Intratumoral administration of carboplatin for treatment of squamous cell carcinomas of the nasal plane in cats. Am J Vet Res 1996;57:205-210. (Pubitemid 26057714)
2. Fry DR, Snelling SR, Beck C. Partial remission of an inoperable extraskeletal osteosarcoma in association with carboplatin in a cat. Aust Vet Pract 2003;33:103-104. (Pubitemid 37414493)
3. Sparkes A, Murphy S, McConnell F, et al. Palliative intracavitary carboplatin therapy in a cat with suspected pleural mesothelioma. J Feline Med Surg 2005;7:313-316. (Pubitemid 41403774)
4. Bailey DB, Rassnick KM, Erb HN, et al. Effect of glomerular filtration rate on clearance and myelotoxicity of carboplatin in cats with tumors. Am J Vet Res 2004;65:1502-1507. (Pubitemid 39561991)
5. Hahn KA, McEntee MF, Daniel GB, et al. Hematologic and systemic toxicoses associated with carboplatin administration in cats. Am J Vet Res 1997;58:677-679. (Pubitemid 27293566)
6. Lund EM, Armstrong PJ, Kirk CA, et al. Health status and population characteristics of dogs and cats examined at private veterinary practices in the United States. J Am Vet Med Assoc 1999;214:1336-1341. (Pubitemid 129535556)
7. Lulich JP, Osborne CA, O'Brien TD, et al. Feline renal failure: questions, answers, questions. Compend Contin Educ Pract Vet 1992;14:127-153.
8. Gibaldi M. Introduction to pharmacokinetics. In: Biopharmaceutics and clinical pharmacokinetics. 4th ed. Philadelphia: Lea & Febiger, 1991;1-13.
9. McClellan JM, Goldstein RE, Erb HN, et al. Effects of administration of fluids and diuretics on glomerular filtration rate, renal blood flow, and urine output in healthy awake cats. Am J Vet Res 2006;67:715-722. (Pubitemid 44082183)
10. Rogers KS, Komkov A, Brown SA, et al. Comparison of four methods of estimating glomerular filtration rate in cats. Am J Vet Res 1991;52:961-964.
11. Barthez PY, Chew DJ, DiBartola SP. Effect of sample number and time on determination of plasma clearance of technetium Tc 99m pentetate and orthoiodohippurate sodium I 131 in dogs and cats. Am J Vet Res 2000;61:280-285. (Pubitemid 30121149)
12. 131I-orthoiodohippurate plasma clearance in dogs and cats. J Vet Intern Med 2001;15:200-208. (Pubitemid 33722462)
13. 2). In: Plumbs veterinary drug handbook. 5th ed. Ames, Iowa: Blackwell Publishing, 2005;869.
14. Veterinary Co-operative Oncology Group. Veterinary co-operative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats version 1.0. Vet Comp Oncol 2004;2:194-213.
15. Dawson B, Trapp RG. Research questions about relationships among variables. In: Basic and clinical biostatistics. 4th ed. New York: Lange Medical Books, 2004;190-220.
16. Kisseberth WC, Vail DM, Yaissle J, et al. Phase I clinical evaluation of carboplatin in tumor-bearing cats: a Veterinary Cooperative Oncology Group study. J Vet Intern Med 2008;22:83-88. (Pubitemid 351361455)
17. Price GS, Frazier DL. Use of body surface area (BSA)-based dosages to calculate chemotherapeutic drug dose in dogs: I. Potential problems with current BSA formulae. J Vet Intern Med 1998;12:267-271.
18. Rassnick KM, Moore AS, Northrup NC, et al. Phase I trial and pharmacokinetic analysis of ifosfamide in cats with sarcomas. Am J Vet Res 2006;67:510-516. (Pubitemid 44082070)
19. Mauldin GN, Matus RE, Patnaik AK, et al. Efficacy and toxicity of doxorubicin and cyclophosphamide used in the treatment of selected malignant tumors in 23 cats. J Vet Intern Med 1988;2:60-65.
20. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-1756. (Pubitemid 19272848)
21. Egorin MJ, Van Echo DA, Tipping SJ, et al. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarbo xylato)platinum in patients with impaired renal function. Cancer Res 1984;44:5432-5438. (Pubitemid 15204524)
22. Siddik ZH, Newell DR, Boxall FE, et al. The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats. Biochem Pharmacol 1987;36:1925-1932. (Pubitemid 17100213)
23. Gaver RC, George AM, Duncan GF, et al. The disposition of carboplatin in the beagle dog. Cancer Chemother Pharmacol 1988;21:197-202. (Pubitemid 18116833)
24. Calvert AH, Harland SJ, Newell DR, et al. Phase I studies with carboplatin at the Royal Marsden Hospital. Cancer Treat Rev 1985;12(suppl A):51-57. (Pubitemid 16167900)
25. Calvert AH, Harland SJ, Newell DR, et al. Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol 1982;9:140-147. (Pubitemid 13253279)
26. Egorin MJ, Van Echo DA, Olman EA, et al. Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum. Cancer Res 1985;45:6502-6506. (Pubitemid 16224834)
27. Phillips B. Severe, prolonged bone marrow hypoplasia secondary to the use of carboplatin in an azotemic dog. J Am Vet Med Assoc 1999;215:1250-1252. (Pubitemid 29531820)
28. Miyamoto K. Evaluation of plasma clearance of inulin in clinically normal and partially nephrectomized cats. Am J Vet Res 2001;62:1332-1335. (Pubitemid 33606855)
29. Goy-Thollot I, Chafotte C, Besse S, et al. Iohexol plasma clearance in healthy dogs and cats. Vet Radiol Ultrasound 2006;47:168-173. (Pubitemid 44044729)
30. Miyamoto K. Evaluation of single-injection method of inulin and creatinine as a renal function test in normal cats. J Vet Med Sci 1998;60:327-332. (Pubitemid 128529406)
31. Chu E, DeVita VT. Principles of medical oncology. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 7th ed. Philadelphia: Lippincott Williams & Wilkins, 2005;295-306.